Betapace Articles
Stock Commentary - New York - week to Oct 1, 2007
8 October 2007
Schering AG US sales up 22% in Q2
5 August 2002
Net income up 24% at Schering AG as Betaferon sales stay strong
11 February 2002
Net income up 23% at Schering AG as Betaferon sales stay strong
9 November 2001
Schering AG raises earnings expectations
27 July 2001
Good 1st-half sales and profits at Schering AG
28 July 2000
Wyeth's Cordarone "treatment of choice"
6 April 2000
1999 sales and profits up at Schering AG - updated story
10 February 2000
FDA backs Pfizer's dofetilide, launch slated for early 2000
11 October 1999
Teva profits soar 82% in 2nd quarter
4 August 1999
FDA panel backs Betapace for AF
5 May 1999
Schering AG forecasts 4% 1999 sales growth
17 March 1999
Europe/US sales offset Asian crisis at Schering
9 February 1999
Strong Start To 1998 By Schering AG
5 May 1998
Schering AG Sales And Profits Rise In 1997
20 March 1998
Schering AG To Stay Independent As Sales Grow
9 February 1998
Gyne/Therapeutics Push Schering AG First Half Sales
7 August 1997
Amiodarone Cuts Total Mortality Post-MI, CHF
12 June 1997
Schering AG Posts 13% Sales Hike For 1996
17 February 1997
Difficult Times As Schering AG Marks 125 Years
1 July 1996
Currency Effects Hit Schering AG In 1995
12 February 1996
Flat Interim Results From Schering AG
14 August 1995
B-MS Discontinues d-Sotalol Trial
14 November 1994
SCHERING AG SEES PROFITS DIP
14 February 1994
GOOD 1993 FIRST HALF FOR SCHERING AG
16 August 1993
FDA APPROVES 26 NEWDRUGS IN 1992
25 January 1993
ASPIRIN AND CARDIAC FUNCTIONS
21 December 1992
BERLEX' BETAPACE APPROVED
9 November 1992
SOTALOL BEST, SAYS ARRHYTHMIA STUDY
27 April 1992
STRONG INCREASES IN 1991 AT BRISTOL-MYERS SQUIBB
20 April 1992
CAST EFFECTS ON ANTI-ARRHYTHMICS
20 January 1992
Showing 1-33 of 33 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
